Nov. 14, 2005 — The U.S. Food and Drug Administration (FDA) has approved a real-time cardiopulmonary resuscitation monitoring and feedback device to assist responders in providing appropriate ...
Accumetrics, Inc., developer of the market-leading VerifyNow® System, announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to ...
SAN DIEGO--(BUSINESS WIRE)--Accumetrics, Inc., developer of the VerifyNow ® System, the first rapid and easy-to-use system for measuring platelet reactivity to multiple antiplatelet agents, announced ...
Lower achieved platelet reactivity associated with better cardiovascular: Outcomes in GRAVITAS trial
Compared to patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence of cardiovascular death, ...
SAN DIEGO, May 17, 2011 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow(R) System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple ...
SAN DIEGO, Nov. 19 Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was ...
Following Stent Placement, Low Platelet Reactivity at Time of Discharge and After 30 Days Leads to 50% Reduction in Cardiovascular Events "These new findings from GRAVITAS demonstrate that patients ...
The addition of the therapeutic window claim marks the second major change to the intended use of the CE marked VerifyNow P2Y12 Test in the last two years. With a similar claim currently being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results